Who
Thomas G. Wiggans
Director
Company insider
Files Form 4 as: Director, Jasper Therapeutics; Director, Pacira BioSciences; Director, Annexon; Director, CymaBay Therapeutics; Chief Executive Officer, Pardes Biosciences; Director, Forma Therapeutics Holdings; CEO & Chairman of the Board, Dermira; Director, Onyx Pharmaceuticals.
In numbers
- Trades disclosed
- 301
- Buys
- 22
- Sells
- 37
- Bought
- $1.0M
- Sold
- $8.3M
- Companies
- 14
- Companies where not an officer
- 10
- First trade
- 2 Sep 2005
- Last trade
- 31 Jul 2026
- Last filed
- 4 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 31 Jul 2026filed 4 Aug 2026 | JSPR Jasper Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,500 at $0.00 | filing |
| 31 Jul 2026filed 4 Aug 2026 | JSPR Jasper Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,500 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | PCRX Pacira BioSciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —32,675 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | PCRX Pacira BioSciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —32,675 at $0.00 | filing |
| 22 Sep 2025filed 24 Sep 2025 | JSPR Jasper Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | —41,000 | filing |
| 22 Sep 2025filed 24 Sep 2025 | JSPR Jasper TherapeuticsBiotechnology | SEC FORM 4 Bought | $100K41,000 at $2.43 | filing |
| 3 Jul 2025filed 3 Jul 2025 | JSPR Jasper Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,500 at $0.00 | filing |
| 5 Jun 2025filed 9 Jun 2025 | ANNX Annexonoption or derivative · Biotechnology | SEC FORM 4 Code A | —55,000 at $0.00 | filing |
| 6 Jun 2024filed 10 Jun 2024 | JSPR Jasper Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,500 at $0.00 | filing |
| 5 Jun 2024filed 7 Jun 2024 | ANNX Annexonoption or derivative · Biotechnology | SEC FORM 4 Code A | —44,000 at $0.00 | filing |
| 22 Mar 2024filed 22 Mar 2024 | CymaBay Therapeuticsoption or derivative | SEC FORM 4 Code D | —80,000 | filing |
| 22 Mar 2024filed 22 Mar 2024 | CymaBay Therapeuticsoption or derivative | SEC FORM 4 Code D | —67,000 | filing |
| 22 Mar 2024filed 22 Mar 2024 | CymaBay Therapeuticsoption or derivative | SEC FORM 4 Code D | —25,000 | filing |
| 22 Mar 2024filed 22 Mar 2024 | CymaBay Therapeuticsoption or derivative | SEC FORM 4 Code D | —14,010 | filing |
| 24 Jan 2024filed 26 Jan 2024 | CymaBay Therapeuticsoption or derivative | SEC FORM 4 Code A | —14,010 at $0.00 | filing |
| 28 Nov 2023filed 30 Nov 2023 | JSPR Jasper TherapeuticsBiotechnology | SEC FORM 4 Bought | $6,50010,000 at $0.65 | filing |
| 21 Nov 2023filed 22 Nov 2023 | JSPR Jasper TherapeuticsBiotechnology | SEC FORM 4 Bought | $6,40010,000 at $0.64 | filing |
| 20 Nov 2023filed 20 Nov 2023 | JSPR Jasper TherapeuticsBiotechnology | SEC FORM 4 Bought | $6,30010,000 at $0.63 | filing |
| 17 Nov 2023filed 20 Nov 2023 | JSPR Jasper TherapeuticsBiotechnology | SEC FORM 4 Bought | $6,00010,000 at $0.60 | filing |
| 16 Nov 2023filed 20 Nov 2023 | JSPR Jasper TherapeuticsBiotechnology | SEC FORM 4 Bought | $6,00010,000 at $0.60 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
Related people
Nobody else traded the same names lately.